ConductScience.org, home
IGF2BP3: insulin like growth factor 2 mRNA binding protein 3
API referenceFor AI assistants

Gene · 10643

Papers3,038

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

121 to 140 of 3,038

Download this page as JSON
TitleJournalYearPMIDFound bySource
IGF2BP3 inhibition: another home run for RNA-binding protein targeting in hematological malignancies.Haematologica202641641633PubTator, text miningPubMed
circMFN2 Regulates the IGF2BP3-PDK4 to Ameliorate Pulmonary Hypertension.Hypertension202641641542PubTator, text miningPubMed
Oncolytic viruses: advanced strategies in cancer therapy.Signal Transduct Target Ther202641639062PubTator, text miningPubMed
RBM15 Enhances 5-Fluorouracil Drug Sensitivity and Suppresses Gastric Cancer Progression by Modulating N6-Methyladenosine Modification of ECT2-Dependent IGF2BP3.Research (Wash D C)202641635511PubTator, text miningPubMed
The molecular mechanism of IGF2BP3 promoting the malignant progression of lung cancer.Cancer Cell Int202641634702PubTator, text miningPubMed
RBM15/IGF2BP3 promotes immune escape in bladder cancer by enhancing m6A modification of PFKFB4.Int J Biol Macromol202641579989PubTator, text miningPubMed
IGF2BP3-dependent glutamine/BCAA metabolic rewiring rejuvenates aged human adipose-derived stem cells for enhanced tissue regeneration.Cell Discov202641559031PubTator, text miningPubMed
IGF2BP3 Enhances GSDMD Stability and Blocks JNK Signaling Activation to Promote Eyelid Basal Cell Carcinoma Pyroptosis in an m6A-Dependent Manner.Curr Eye Res202641552912PubTator, text miningPubMed
IGF2BP3 in Multi-System Diseases: Molecular Mechanisms, Pathological Roles and Translational Insights.Cell Biochem Biophys202641546815PubTator, text miningPubMed
Dysregulation of PCSK9 via m6A-dependent epitranscriptomic programs fosters hepatocellular carcinoma progression.Cancer Lett202641534785PubTator, text miningPubMed
IGF2BP3/m6A-mediated intron retention isoform of DUSP6 promotes cisplatin resistance in nasopharyngeal carcinoma by inhibiting pyroptosis.BMC Cancer202641526845PubTator, text miningPubMed
Hepatic Mettl14 Knockout Disrupts Bile Acid Homeostasis and Alters Fecal Microbiota Composition.FASEB J202641524217PubTator, text miningPubMed
VIRMA/IGF2BP3-mediated ANLN upregulation promotes intrahepatic cholangiocarcinoma growth by forming a positive feedback loop with RhoA/YAP1/TEAD1 signaling pathway.Cell Death Dis202641513610PubTator, text miningPubMed
CircZBTB44-Encoded Peptide ZBTB44-342aa Alleviates Aortic Valve Calcification Via cGAS-STING Inhibition.Circ Res202641487094PubTator, text miningPubMed
USP10 promotes cell proliferation and gemcitabine resistance in pancreatic cancer by the regulation of IGF2BP3-STEAP3.Oncogene202641381842PubTator, text miningPubMed
M6A reader IGF2BP3 stabili1zes SLC7A11 to antagonize ferroptosis and promote gastric tumorigenesis.Cell Signal202641352745PubTator, text miningPubMed
IGF2BP3 Promoted the Overproliferation of AML Cells via Stability of NRXN2 mRNATurk J Haematol202641263466PubTator, text miningPubMed
Mechanistic exploration of IGF2BP3-mediated m6A dynamics in diabetic retinopathy for therapeutic interventions through in silico approaches.J Mol Graph Model202641242175PubTator, text miningPubMed
Chromosomal rearrangement-enhanced mRNA stability drives the oncogenic potential of fusion genes in pediatric leukemia.Haematologica202641230692PubTator, text miningPubMed
TOP2A, Stabilized by IGF2BP3 in an m6A-Dependent Manner, Drives Macrophage Recruitment and M2 Polarization in Hepatocellular Carcinoma by YAP1-Mediated CCL2 Activation.Mol Carcinog202641176641PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Previous pageNext page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/10643/papers?page=7

API referenceFor AI assistants